{"filing":{"accession_number":"0001683168-26-004268","cik":"0001652935","ticker":"ACTU","company_name":"ACTUATE THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-05-22","report_date":null,"primary_document":"actuate_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316826004268/actuate_8k.htm"},"events":[{"id":10725,"run_id":9407,"accession_number":"0001683168-26-004268","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This Item 5.07 disclosure reports the final voting results from Actuate Therapeutics' May 21, 2026 Annual Meeting of Stockholders, including the election of two Class II directors (Aaron G.L. Fletcher and Jason Keyes) and ratification of Crowe LLP as independent auditor. The tabulated vote counts for each proposal are the core content, matching the shareholder_vote_results taxonomy precisely.","company_name":"ACTUATE THERAPEUTICS, INC.","ticker":"ACTU","filing_date":"2026-05-22","form":"8-K","submitted_at":null,"items":[{"id":7110,"accession_number":"0001683168-26-004268","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the final voting results from Actuate Therapeutics' May 21, 2026 Annual Meeting of Stockholders, including the election of two Class II directors (Aaron G.L. Fletcher and Jason Keyes) and ratification of Crowe LLP as independent auditor. The tabulated vote counts for each proposal are the core content, matching the shareholder_vote_results taxonomy precisely.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:58:44.474678+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7110,"accession_number":"0001683168-26-004268","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the final voting results from Actuate Therapeutics' May 21, 2026 Annual Meeting of Stockholders, including the election of two Class II directors (Aaron G.L. Fletcher and Jason Keyes) and ratification of Crowe LLP as independent auditor. The tabulated vote counts for each proposal are the core content, matching the shareholder_vote_results taxonomy precisely.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:58:44.474678+00:00","company_name":"ACTUATE THERAPEUTICS, INC.","ticker":"ACTU","filing_date":"2026-05-22"}]}